Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds: A Randomized Controlled Trial
Sponsor: Brigham and Women's Hospital
Listed as NCT03452072, this PHASE2/PHASE3 trial focuses on Surgical Wound and Wound Heal and remains completed. Sponsored by Brigham and Women's Hospital, it has been updated 11 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Feb 2022 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
-
May 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 6 earlier versions
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2019 — Mar 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2019 — Oct 2019 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Aug 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Brigham and Women's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .